Zacks Research Brokers Reduce Earnings Estimates for PBH

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Research analysts at Zacks Research lowered their Q2 2026 earnings estimates for shares of Prestige Consumer Healthcare in a report released on Tuesday, January 14th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.18 for the quarter, down from their prior estimate of $1.19. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q3 2026 earnings at $1.24 EPS and Q3 2027 earnings at $1.30 EPS.

Several other research firms have also recently commented on PBH. StockNews.com cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Thursday. Jefferies Financial Group reaffirmed a "hold" rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson reiterated a "buy" rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a research note on Monday, December 9th. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of "Hold" and an average price target of $85.25.

Prestige Consumer Healthcare Stock Up 0.3 %

NYSE:PBH traded up $0.23 on Friday, reaching $78.51. The stock had a trading volume of 94,888 shares, compared to its average volume of 275,736. The company has a 50-day moving average of $80.56 and a 200 day moving average of $74.41. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a market cap of $3.88 billion, a P/E ratio of 19.10, a price-to-earnings-growth ratio of 2.08 and a beta of 0.51. Prestige Consumer Healthcare has a 12-month low of $58.22 and a 12-month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business's quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the firm posted $1.07 earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PBH. Quest Partners LLC grew its position in Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after buying an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after acquiring an additional 433 shares during the period. nVerses Capital LLC boosted its holdings in shares of Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company's stock valued at $43,000 after acquiring an additional 400 shares in the last quarter. Huntington National Bank increased its stake in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after acquiring an additional 181 shares during the period. Finally, International Assets Investment Management LLC raised its holdings in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock worth $83,000 after purchasing an additional 1,138 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Insiders Place Their Bets

In other news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider William P'pool sold 8,987 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 over the last quarter. Insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.